The company’s troubles are of its own making and are fixable
Dr. Martens (DOCS) 72.1p Loss to date: 21.6% In mid-December 2023 we said the knock-down share price of iconic footwear brand Dr. Martens (DOCS) was too tempting to resist despite the company delivering four profit warnings. Our rationale was simple – either the self-inflicted operational issues would be fixed by the current management or the business would be taken over by an opportunistic predator who recognised the untapped value...